BACKGROUND: Bitter tasting drugs represent a large portion of active pharmaceutical ingredients. Mini-tablets are specifically designed for patients with difficulty in swallowing particular in young children up to 10 years of age, geriatric patients and patients with esophagitis. OBJECTIVE: The present study was aimed to prepare, taste-masked mini-tablets, which are easily swallowed dosage forms, primarily to be used by pediatric and geriatric patients. METHODS: Ketoprofen (10%-50% w/w) and Eudragit® EPO were blended and extruded with a 5-mm strand die and cut into consistent mini-tablets by using an adapted downstream pelletizer. RESULTS: Differential scanning calorimetry and polarized light microscopy-hot stage microscopy studies confirmed that the binary mixtures were miscible under the employed extrusion temperatures. In-vitro release studies showed that drug release was less than 0.5% within the first 2 min in simulated salivary fluid (pH 6.8) and more than 90% in the first 20 min in gastric media (pH 1.0). The results of the electronic tongue analysis were well correlated with the drug release profile of the mini-tablets in the artificial saliva. Scanning electron microscopy revealed no cracks on the surface of the minitablets, confirming that the mini-tablets were compact solids. Chemical imaging confirmed the uniform distribution of ketoprofen inside the polymer matrices. CONCLUSION: Eudragit® EPO containing ketoprofen at various drug loads were successfully melt extruded into tastedmasked mini-tablets. The reduced drug release at salivary pH correlated well with Astree e-Tongue studies for taste masking efficiency.
BACKGROUND: Bitter tasting drugs represent a large portion of active pharmaceutical ingredients. Mini-tablets are specifically designed for patients with difficulty in swallowing particular in young children up to 10 years of age, geriatric patients and patients with esophagitis. OBJECTIVE: The present study was aimed to prepare, taste-masked mini-tablets, which are easily swallowed dosage forms, primarily to be used by pediatric and geriatric patients. METHODS:Ketoprofen (10%-50% w/w) and Eudragit® EPO were blended and extruded with a 5-mm strand die and cut into consistent mini-tablets by using an adapted downstream pelletizer. RESULTS: Differential scanning calorimetry and polarized light microscopy-hot stage microscopy studies confirmed that the binary mixtures were miscible under the employed extrusion temperatures. In-vitro release studies showed that drug release was less than 0.5% within the first 2 min in simulated salivary fluid (pH 6.8) and more than 90% in the first 20 min in gastric media (pH 1.0). The results of the electronic tongue analysis were well correlated with the drug release profile of the mini-tablets in the artificial saliva. Scanning electron microscopy revealed no cracks on the surface of the minitablets, confirming that the mini-tablets were compact solids. Chemical imaging confirmed the uniform distribution of ketoprofen inside the polymer matrices. CONCLUSION: Eudragit® EPO containing ketoprofen at various drug loads were successfully melt extruded into tastedmasked mini-tablets. The reduced drug release at salivary pH correlated well with Astree e-Tongue studies for taste masking efficiency.
Authors: Michael M Crowley; Feng Zhang; Michael A Repka; Sridhar Thumma; Sampada B Upadhye; Sunil Kumar Battu; James W McGinity; Charles Martin Journal: Drug Dev Ind Pharm Date: 2007-09 Impact factor: 3.225
Authors: Mohammed Maniruzzaman; Joshua S Boateng; Babur Z Chowdhry; Martin J Snowden; Dennis Douroumis Journal: Drug Dev Ind Pharm Date: 2013-06-13 Impact factor: 3.225
Authors: Manjeet B Pimparade; Joseph T Morott; Jun-Bom Park; Vijay I Kulkarni; Soumyajit Majumdar; S N Murthy; Zhuoyang Lian; Elanor Pinto; Vivian Bi; Thomas Durig; Reena Murthy; H N Shivakumar; K Vanaja; P C Kumar; Michael A Repka Journal: Int J Pharm Date: 2015-04-15 Impact factor: 5.875
Authors: Sultan M Alshehri; Jun-Bom Park; Bader B Alsulays; Roshan V Tiwari; Bjad Almutairy; Abdullah S Alshetaili; Joseph Morott; Sejal Shah; Vijay Kulkarni; Soumyajit Majumdar; Scott T Martin; Sanjay Mishra; Lijia Wang; Michael A Repka Journal: J Drug Deliv Sci Technol Date: 2015-06-01 Impact factor: 3.981
Authors: Abdullah S Alshetaili; Bjad K Almutairy; Saad M Alshahrani; Eman A Ashour; Roshan V Tiwari; Sultan M Alshehri; Xin Feng; Bader B Alsulays; Soumyajit Majumdar; Nigel Langley; Karl Kolter; Andreas Gryczke; Scott T Martin; Michael A Repka Journal: Drug Dev Ind Pharm Date: 2016-05-04 Impact factor: 3.225